Comparer des méthodes
Examinez les méthodes sélectionnées côte à côte ; les lignes qui diffèrent sont mises en évidence.
| Étude de phase IV méta-analytique× | Méta-analyse en réseau× | |
|---|---|---|
| Domaine≠ | Épidémiologie | Synthèse des données probantes |
| Famille | Process / pipeline | Process / pipeline |
| Année d'origine≠ | 1990s–2000s (formalised as regulatory requirement context grew) | 2002 |
| Auteur d'origine≠ | Developed through the convergence of meta-analytic methods (Glass, 1976; Hedges & Olkin, 1985) and post-marketing pharmacoepidemiology frameworks | Lumley (2002) |
| Type≠ | Evidence synthesis applied to post-marketing observational and trial data | Method |
| Source fondatrice≠ | Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. A., & Song, F. (2000). Methods for Meta-Analysis in Medical Research. Wiley. ISBN: 978-0471490661 | Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324. DOI ↗ |
| Alias≠ | Phase IV meta-analysis, post-marketing meta-analysis, pharmacoepidemiologic meta-analysis, post-approval systematic review and meta-analysis | Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis |
| Apparentées≠ | 3 | 1 |
| Résumé≠ | A meta-analytic Phase IV study pools and quantitatively synthesises data from multiple Phase IV (post-marketing) sources — including observational cohorts, registries, spontaneous adverse-event databases, and post-approval randomised trials — to produce a single, more precise estimate of a drug or device's real-world effectiveness, safety, or utilisation pattern. By applying meta-analytic weighting to heterogeneous post-marketing evidence, it bridges the gap between tightly controlled pre-approval trials and the complexity of routine clinical practice. | Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied. |
| ScholarGateJeu de données ↗ |
|
|